Gil Roth07.22.13
Dr. Maurizio Denaro has been named general manager of Aptuit's Center for Discovery & Development in Verona, Italy, effective July 15, 2013. He was also named to the company's Executive Committee. Dr. Denaro has held corporate and R&D leadership roles at global life science companies in Europe and the U.S., including Bracco Imaging, where he was responsible for the ultrasound business unit, Marion Merrell Dow, OSI Pharmaceuticals, Amylin Pharmaceuticals and Hoechst Marion Roussel.
Stuart Needleman, Aptuit's president and chief operating officer, cited Dr. Denaro's global experience as a highly successful R&D executive, commenting, "We are delighted to have Maurizio on board, and I am pleased that he will be bringing us his expertise in the global life science industry. In every way, we are looking forward to the continued growth and success of our uniquely integrated outsourcing solution for discovery and development in Verona, optimistic that it will prosper under Maurizio's talented leadership."
Dr. Denaro remarked, "In only three years, Aptuit's drug discovery and development site in Verona has become a very valuable resource for life sciences companies around the world. It is my objective to maintain the steady progress that has been made to date while also initiating further growth through scientific excellence and a commitment to industry-leading service."
Stuart Needleman, Aptuit's president and chief operating officer, cited Dr. Denaro's global experience as a highly successful R&D executive, commenting, "We are delighted to have Maurizio on board, and I am pleased that he will be bringing us his expertise in the global life science industry. In every way, we are looking forward to the continued growth and success of our uniquely integrated outsourcing solution for discovery and development in Verona, optimistic that it will prosper under Maurizio's talented leadership."
Dr. Denaro remarked, "In only three years, Aptuit's drug discovery and development site in Verona has become a very valuable resource for life sciences companies around the world. It is my objective to maintain the steady progress that has been made to date while also initiating further growth through scientific excellence and a commitment to industry-leading service."